Table 1.
Demographic and Disease Characteristics of All the Trial Patients at Baseline.*
| Characteristic | Lenvatinib plus Pembrolizumab (N = 411) | Chemotherapy (N = 416) |
|---|---|---|
| Age | ||
| Median (range) — yr | 64 (30–82) | 65 (35–86) |
| <65 yr — no. (%) | 206 (50.1) | 204 (49.0) |
| Race — no. (%)† | ||
| White | 261 (63.5) | 246 (59.1) |
| Black | 17 (4.1) | 14 (3.4) |
| Asian | 85 (20.7) | 92 (22.1) |
| Geographic region — no. (%)‡ | ||
| Region 1 | 234 (56.9) | 240 (57.7) |
| Region 2 | 177 (43.1) | 176 (42.3) |
| MMR status — no. (%) | ||
| pMMR | 346 (84.2) | 351 (84.4) |
| dMMR | 65 (15.8) | 65 (15.6) |
| ECOG performance-status score — no. (%)§ | ||
| 0 | 246 (59.9) | 241 (57.9) |
| 1 | 164 (39.9) | 175 (42.1) |
| History of pelvic irradiation — no. (%) | 174 (42.3) | 186 (44.7) |
| Histologic features at initial diagnosis — no. (%)¶ | ||
| Endometrioid carcinoma | 243 (59.1) | 254 (61.1) |
| High grade | 94 (22.9) | 90 (21.6) |
| Low grade | 59 (14.4) | 54 (13.0) |
| Not specified‖ | 90 (21.9) | 110 (26.4) |
| Serous carcinoma | 103 (25.1) | 115 (27.6) |
| Clear-cell carcinoma | 30 (7.3) | 17 (4.1) |
| Mixed features | 22 (5.4) | 16 (3.8) |
Percentages may not total 100 because of rounding. The term dMMR denotes mismatch repair–deficient, MMR mismatch repair, and pMMR mismatch repair–proficient.
Race was reported by the patient. Data on race were missing for 36 patients (8.8%) in the lenvatinib-pembrolizumab group and for 44 (10.6%) in the chemotherapy group. Other races or ethnic groups (reported by 12 patients [2.9%] in the lenvatinib-pembrolizumab group and by 20 [4.8%] in the chemotherapy group) included American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, and multiple.
Region 1 was defined as Australia, Canada, Europe, Israel, New Zealand, and the United States, and region 2 as the rest of the world.
Eastern Cooperative Oncology Group (ECOG) performance-status scores are assessed on a 5-point scale, with higher scores indicating greater disability. One patient in the lenvatinib–pembrolizumab group had an ECOG performance-status score of 3 (was enrolled in error).
Information regarding histologic features at diagnosis for categories that included less than 5% of the patients is provided in Table S2.
The “not specified” category included endometrioid carcinoma (grade not specified) nd endometrioid carcinoma with squamous differentiation.